. 2020 May 15;9(13):4686–4698. doi: 10.1002/cam4.3064

Table 1.

Patient characteristics by type of parenteral nutrition and whether they received chemotherapy during the study period

	Overall (N = 761)		Chemotherapy received							No chemotherapy received
	Overall (N = 761)		SPN/CT⁺ (N = 376)			TPN/CT⁺ (N = 99)				SPN/CT^‐ (N = 191)			TPN/CT^‐ (N = 95)
	N	%	N	%	N		%	P¹	N		%	P²	N	%	P³
Sex
Female	380	49.9	197	52.4	41		41.4		102		53.4		40	42.1
Age (years)
Mean (SD)	62.90	(10.28)	60.07	(9.15)	62.07		(9.89)		66.12		(10.84)	<.01	68.49	(9.73)	<.01
Age categories (years)
<70	555	72.9	325	86.4	75		75.8		113		59.2		42	44.2
≥70	206	27.1	51	13.6	24		24.2	<.01	78		40.8	<.01	53	55.8	<.01
Actual weight (kg)
Mean (SD)	58.42	(10.92)	59.56	(11.32)	58.74		(10.12)		56.11		(10.23)	<.01	58.21	(10.92)
BMI (kg/m²)
Mean (SD)	21.37	(3.76)	21.75	(4.01)	21.62		(3.60)		20.54		(3.12)	<.01	21.23	(3.84)
BMI class
<20.5 kg/m²	334	43.9	149	39.6	37		37.4		101		52.9		47	49.5
≥ 20.5 kg/m²	427	56.1	227	60.4	62		62.6		90		47.1	<.01	48	50.5
Weight loss (%) categories ^a
≤10.0%	233	30.6	162	43.1	12		12.1		52		27.2		7	7.4
10.1%‐15%	187	24.6	109	29.0	21		21.2		40		20.9		17	17.9
15.1%‐20%	181	23.8	59	15.7	35		35.4		49		25.7		38	40.0
>20%	160	21.0	46	12.2	31		31.3	<.01	50		26.2	<.01	33	34.7	<.01
BMI‐adjusted weight loss
Grade 2	26	3.4	18	4.8	2		2.0		5		2.6		1	1.1
Grade 3	264	34.7	177	47.1	24		24.2		49		25.7		14	14.7
Grade 4	471	61.9	181	48.1	73		73.7	<.01	137		71.7	<.01	80	84.2	<.01
PG‐SGA
B ^b	242	31.8	171	45.5	12		12.1		52		27.2		7	7.4
C ^c	519	68.2	205	54.5	87		87.9	<.01	139		72.8	<.01	88	92.6	<.01
Oral calorie intake (kcal/day)
<500	322	42.3	65	17.3	—		—		63		33.0		—	—
500‐1000	409	53.8	291	77.4	—		—		118		61.8		—	—
>1000	30	3.9	20	5.3	—		—		10		5.2	<.01	—	—
Oral protein intake (g/day)
<20	353	46.39	84	22.3	—		—		75		39.3		—	—
≥20	408	53.61	292	77.7	—		—		116		60.7	<.01	—	—
Tumor site
Ovary	47	6.2	24	6.4	6		6.1		11		5.8		6	6.3
Gastrointestinal	564	74.1	293	77.9	72		72.7		134		70.2		65	68.4
Other	150	19.7	59	15.7	21		21.2		46		24.1		24	25.3
Metastatic cancer
No	301	39.6	174	46.3	27		27.3		67		35.1		33	34.7
Yes	460	60.5	202	53.7	72		72.7	<.01	124		64.9	<.05	62	65.3	<.05
Peritoneal carcinomatosis
No	533	70.0	288	76.6	54		54.6		126		66.0		65	68.4
Yes	228	30.0	88	23.4	45		45.5	<.01	65		34.0	<.01	30	31.6
Cancer staging
II/III	220	28.9	137	36.4	19		19.2		47		24.6		17	17.9
IV	541	71.1	239	63.6	80		80.8	<.01	144		75.4	<.01	78	82.1	<.01
KPS
50	102	13.4	8	2.1	11		11.1		43		22.5		40	42.1
60	222	29.2	95	25.3	33		33.3		65		34.0		29	30.5
70	387	50.9	230	61.2	55		55.6		77		40.3		25	26.3
80‐90	50	6.6	43	11.4	.		.	<.01	6		3.1	<.01	1	1.1	<.01
Albumin
<3.5 g/dL	430	56.5	163	43.4	62		62.6		123		64.4		82	86.3
≥3.5 g/dL	331	43.5	213	56.7	37		37.4	<.01	68		35.6	<.01	13	13.7	<.01
CRP
≤10 mg/L	390	51.2	261	69.4	33		33.3		78		40.8		18	18.9
>10 mg/L	371	48.8	115	30.6	66		66.7	<.01	113		59.2	<.01	77	81.1	<.01
mGPS
0	390	51.3	261	69.4	33		33.3		78		40.8		18	19.0
1	99	13.0	45	12.0	18		18.2		28		14.7		8	8.4
2	272	35.7	70	18.6	48		48.5	<.01	85		44.5	<.01	69	72.6	<.01

All patient characteristics were at the time of home parenteral nutrition start.

Abbreviations: BMI, body mass index; CRP, C‐reactive protein; CT⁻, no chemotherapy received; CT+, chemotherapy received; ECOG, Eastern Cooperative Oncology Group; KPS, Karnofsky Performance Status; mGPS, modified Glasgow Prognostic Score; PG‐SGA, Patient‐Generated Subjective Global Assessment; SD, standard deviation; SPN, supplemental parenteral nutrition; TPN, total parenteral nutrition.

P ¹: the groups compared were SPN/CT⁺ vs. TPN/CT⁺; P ²: SPN/CT⁺ vs. SPN/CT^‐; P ³: SPN/CT⁺ vs. TPN/CT^‐. Where the comparison was significant, P‐value is reported.

^{^a}

In the last 3 months before home parenteral nutrition (HPN) start.

^{^b}

Moderately malnourished or suspected malnutrition.

^{^c}

Severely malnourished.